FDA awards $2.3M to back immunosuppressive-drug study

11/7/2013 | American City Business Journals

The FDA has awarded transplant researchers from the University of Cincinnati $2.3 million to support two clinical trials that will assess the safety and efficacy of generic immunosuppressive-drug tacrolimus, a drug that lowers the risk of organ rejection in transplant patients. The three-year grant will support the studies in high-risk transplant recipients who have converted from branded tacrolimus to a generic version.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC